Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | CDC25A | P30304 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17570242 | 0.81 | GSK3B (0.34) | GSK3BALDH1A1MAPK1C3AR1KMT2A | |
| SCHEMBL12239808 | 0.81 | GSK3B (0.32) | GSK3BALDH1A1MAPK1 | |
| SCHEMBL2142348 | 0.81 | PLAU (0.32) | GSK3BALDH1A1MAPK1 | |
| SCHEMBL2844137 | 0.77 | MEN1 (0.49) | C3AR1KMT2AMEN1NAMPT | |
| SCHEMBL2847781 | 0.73 | IDE (0.42) | GSK3BADAMTS5 | |
| SCHEMBL2841809 | 0.73 | ADAMTS5 (0.39) | ALDH1A1KMT2AMEN1ADAMTS5ADAM17 | |
| SCHEMBL19393149 | 0.71 | C3AR1 (0.31) | C3AR1 | |
| SCHEMBL17570239 | 0.70 | ADAMTS5 (0.31) | ALDH1A1MAPK1ADAMTS5 | |
| SCHEMBL2846071 | 0.68 | MEN1 (0.49) | ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL2847811 | 0.68 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | GSK3B 3273/4885ALDH1A1 1317/4885MAPK1 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.